Drug resistant activity of prostate cancer may be modulated by upregulation of LOXL1-AS1 and EGFR and downregulation of miR-let-7a-5p, predicting miR-let-7a-5p and EGFR are negatively regulated by LOXL1-AS1 and miR-let-7a-5p, respectively (91). The gene discussed is LOXL1; the disease is prostate carcinoma.